
-
Polls open in Australian vote swayed by inflation, Trump
-
Russell clocks second fastest 100m hurdles in history at Miami meeting
-
Germany move against far-right AfD sets off US quarrel
-
Billionaire-owned Paris FC win promotion and prepare to take on PSG
-
Teenager Antonelli grabs pole for Miami sprint race
-
Man City climb to third as De Bruyne sinks Wolves
-
Mercedes' Wolff backs Hamilton to come good with Ferrari
-
'Devastated' Prince Harry says no UK return but seeks reconciliation
-
Elway agent death likely accidental: report
-
Turkish Cypriots protest new rule allowing hijab in school
-
Germany's AfD dealt blow with right-wing extremist label
-
Trump NASA budget prioritizes Moon, Mars missions over research
-
Hard-right romps through UK polls slapping aside main parties
-
Rangers hire two-time NHL champion Sullivan as coach
-
Haaland on bench for Man City as striker returns ahead of schedule
-
US designates two Haitian gangs as terror groups
-
Lower profits at US oil giants amid fall in crude prices
-
NBA icon Popovich stepping down as Spurs coach after 29 seasons
-
'Devastated' Prince Harry says no return to UK but seeks royal reconciliation
-
Grande scratched from Kentucky Derby
-
Carney vows to transform Canada economy to withstand Trump
-
Prince Harry says he would 'love' to reconcile with family
-
Major offshore quake causes tsunami scare in Chile, Argentina
-
GM cuts shift at Canada plant over 'evolving trade environment'
-
F1 extends deal to keep Miami GP until 2041
-
Popovich mixed toughness and spirit to make NBA history
-
US asks judge to break up Google's ad tech business
-
Trump eyes huge 'woke' cuts in budget blueprint
-
Ruud downs Cerundolo to book spot in Madrid Open final
-
Gregg Popovich stepping down as San Antonio Spurs coach after 29 seasons: team
-
Guardiola to take break from football when he leaves Man City
-
Vine escapes to Tour of Romandie 3rd stage win as Baudin keeps lead
-
Olympic 100m medalist Kerley arrested, out of Miami Grand Slam meet
-
Chile, Argentina order evacuations over post-quake tsunami threat
-
Arteta 'pain' as Arsenal fall short in Premier League title race
-
Hard-right romps across UK local elections slapping down main parties
-
US ends duty-free shipping loophole for low-cost goods from China
-
Renewables sceptic Peter Dutton aims for Australian PM's job
-
Australians vote in election swayed by inflation, Trump
-
Syria slams Israeli Damascus strike as 'dangerous escalation'
-
Grand Theft Auto VI release postponed to May 2026
-
Lawyers probe 'dire' conditions for Meta content moderators in Ghana
-
Maresca confident Chelsea can close gap to Liverpool
-
Watchdog accuses papal contenders of ignoring sex abuse
-
Berlin culture official quits after funding cut backlash
-
US hiring better than expected despite Trump uncertainty
-
EU fine: TikTok's latest setback
-
Stocks gain on US jobs data, tariff talks hopes
-
Barca's Ter Stegen to return from long lay-off for Valladolid trip
-
US hiring slows less than expected, unemployment unchanged

MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal(R) G4 HIV-1/2 rapid test for VA, Department of Defense
HALIFAX, NS / ACCESS Newswire / April 17, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) and Lovell® Government Services announced today that they have partnered to serve federal healthcare systems such as the Veterans Health Administration (VHA), the Military Health System (MHS), and the Indian Health Service (IHS). Lovell Government Services will serve as MedMira's Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor to serve these customers through federal contracting systems.
The Reveal® G4 HIV-1/2 antibody rapid test (Reveal® G4 HIV) is the world's fastest HIV rapid test. Based on MedMira's patented Rapid Vertical Flow Technology, the Reveal® G4 HIV offers a simple testing solution with immediate results which do not fade away. Therefore, offering the best rapid testing solution which is FDA approved since 2004. The Reveal® G4 HIV is offered in three convenient formats (Point-of-Care finger-stick whole blood, Laboratory format Serum/Plasma and venipuncture whole blood) to accommodate any health care setting without the need for timing devices. With its unique built-in procedural and reagent control line, an operator can be assured that each test has been performed correctly.
A unique feature of MedMira's patented technology is the elimination of the prozone (hook) effect, a known common issue in traditional serological tests, where a high concentration of antibodies can lead to false-negative results. MedMira's technology avoids this by ensuring antibody binding occurs in a controlled, localized environment, while excess antibodies are washed away. The result is a highly accurate test that maintains reliability across a wide range of antibody levels.
As MedMira's SDVOSB Vendor, Lovell is excited to bring this product to federal healthcare providers. MedMira is now available through the Department of Veterans Affairs' Federal Supply Schedule (FSS), GSA Advantage, the Defense Logistics Agency's Electronic Catalog (ECAT), and the Department of Defense's Distribution and Pricing Agreement (DAPA). Listing products on contract vehicles with Lovell streamlines the acquisition process while helping government agencies meet their SDVOSB procurement goals.
"We're proud to partner with MedMira to bring an advanced rapid testing solution to federal healthcare providers. The speed and reliability of their Reveal® G4 platform supports clinicians in making timely decisions and improves the care experience for our veterans," said Chris Lovell, Major, USMC (Ret.), CEO of Lovell Government Services.
"MedMira is proud to partner with Lovell Government Services, SDVOSB, to support Federal procurement needs through their eCAT, GSA, and VA FSS contract vehicles," said Nicole Crenshaw, VP of Commercial Operations at MedMira. "This strategic partnership provides us with the critical reach into key government markets, enabling greater access to our innovative diagnostic solutions where they're needed most."
About MedMira
MedMira is the developer and owner of Rapid Vertical Flow (RVF)® Technology. The Company's rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company's tests are sold under the Reveal®, Multiplo® and Miriad® brands in global markets. MedMira's HIV rapid test has been the first approved in Canada and the second HIV rapid test approved in the United States.
For more information visit medmira.com. Follow us on Twitter and LinkedIn.
This news release contains forward‐looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events, including statements regarding possible regulatory approval, product launch, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For Media Inquiries:
Markus Meile
[email protected]
902-450-1588
About Lovell Government Services
Lovell Government Services has been a trusted SDVOSB vendor since 2013 with a proven track record of successfully introducing suppliers to the government market. Lovell is a three-time Inc. 5000 honoree and leader in the federal space. They partner with medical and pharmaceutical companies looking to better serve Veteran and military patient populations, increase their federal revenue stream, and win government contracts.
Learn more at www.lovellgov.com
For Media Inquiries:
Jeff McKay
[email protected]
850-912-4680
SOURCE: MedMira, Inc.
View the original press release on ACCESS Newswire
L.Miller--AMWN